- Home
- / Nuvation Bio
Nuvation Bio
Stock Price
$2.3
2024-10-28
Market Capitalization
$784.4 M
2024-10-28
Revenue
$62.9 M
FY, 2025
Nuvation Bio Summary
Company Summary
- Overview
- Nuvation Bio is a biotechnology company developing propriety therapy focused on oncology. Its portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- New York, NY, US | view all locations
- Website
- https://www.nuvationbio.com/
- Cybersecurity rating
Table of Contents
Key People
Gary Hattersley, Chief Scientific Officer
Lisa Deluca, Vice President
Jennifer Fox, Chief Financial Officer
LocationsView all
2 locations detected
New York, NY HQ
United States
Times Square Studios, 1500 Broadway #1401
San Francisco, CA
United States
585 Howard St 3rd Floor, San Francisco
Nuvation Bio Financials
Summary Financials
- Revenue (Q1, 2026)
- $83.2M
- Net income (Q1, 2026)
- $5.4M
- Cash (Q1, 2026)
- $125.4M
- EBIT (Q1, 2026)
- $3.9M
- Enterprise value
- $716.1M